Latest News & Features
Americas
Non-profit organisation I-MAK is attempting to expose the problem at the heart of the patent system—that too often drug patents are wrongfully granted and consequently sick people in poorer countries are being left untreated. LSIPR delves deeper into the issues. 27 October 2015
Asia
Despite the importance of traditional knowledge in many regions, an international treaty governing its control and exploitation does not exist yet—and talks have stalled. LSIPR reports. 27 October 2015
Asia-Pacific
Pharmaceutical trademark owners in Australia should carefully select and register their marks to minimise potential problems associated with including INNs or INN stems, as Geordie Oldfield of Dennemeyer explains. 27 October 2015
Big Pharma
UK court decisions in Warner-Lambert v Actavis seek to define second medical use patent rights, and the recent full trial ruling provides some early guidance on the ‘reasonable foreseeability’ test concerning patent use, says Steve Smith of Potter Clarkson. 27 October 2015
Americas
The future of Brazil’s technological innovation centres, which bring together public and private sector parties to develop mainly life sciences technology, looks bright. Gabriel Di Blasi and Felipe Barros Oquendo of Di Blasi, Parente & Associados report 27 October 2015
Asia
Parties can apply for a compulsory licence in India on several grounds, including that the invention is not worked in the country. Neeti Wilson of Anand and Anand explores the issue further. 27 October 2015
Americas
Despite the US Court of Appeals for the Federal Circuit’s ruling in Amgen v Sandoz, significant uncertainty concerning two key
provisions of the BPCIA remains, as Steve Coyle and Leslie-Anne Maxwell of Cantor Colburn describe. 27 October 2015
Americas
US-based Vertex Pharmaceuticals and CRISPR Therapeutics have agreed a research collaboration to discover and develop new treatments for genetic causes of human diseases. 26 October 2015
Americas
Biotechnology company Luc Therapeutics has agreed to licence its intellectual property covering its depression treatment to Novartis, stating that it will accelerate its programme into how to help people living with psychiatric diseases. 23 October 2015
Americas
Very few members of Congress are informed about the trajectory of section 101 and instead lawmakers are looking at ‘trolls’ and other patent issues, according to a counsel at the Biotechnology Industry Organization. 23 October 2015